<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01087801</url>
  </required_header>
  <id_info>
    <org_study_id>2006-05</org_study_id>
    <nct_id>NCT01087801</nct_id>
  </id_info>
  <brief_title>A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers</brief_title>
  <acronym>CRC2006-05</acronym>
  <official_title>A Placebo Controlled, Double-Blind, Parallel, Multicenter Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ChiRhoClin, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ChiRhoClin, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The following are the study hypothesis:

        -  Secretin administration compared to placebo will result in a statistically significantly
           greater percentage of collected fluid samples being predominantly of exocrine pancreas
           origin when samples are duodenal aspirates.

        -  Secretin administration compared to placebo will result in a statistically significantly
           greater percentage of collected fluid samples meeting the minimum specifications for use
           in the indicated laboratory test of DNA mutational analysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endoscopic Sample</measure>
    <time_frame>First 5 minutes after treatment administration</time_frame>
    <description>Is Volume ≥ 3.5 mL Is HCO3 concentration ≥ 40 mEq/L Is DNA mutational analysis (K-ras-2 gene Fluorescence peak height ≥ 50 Relative Florescence Units panel assessable markers informative ≥ 8).
(Note- The outcome value is boolean (yes or no) as an answer).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Fluid ≥ 3.5mL (Boolean Expression Evaluated as Yes or no).</measure>
    <time_frame>First 5 minutes after treatment administration</time_frame>
    <description>Volume of pancreatic fluid. The volume is the number of mL of pancreatic fluid.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Pancreatic Disease</condition>
  <arm_group>
    <arm_group_label>ChiRhoStim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Human Secretin for Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline for Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ChiRhoStim</intervention_name>
    <description>Human Secretin for Injection</description>
    <arm_group_label>ChiRhoStim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline for Injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented or suspected diagnosis of chronic pancreatitis or suspected diagnosis of
             pancreatic cancer.

          2. Undergoing Endoscopic Procedure.

          3. Age ≥ 18 years.

          4. Willing and able to sign informed consent, meeting IRB guidelines.

          5. Willing and able to meet all study requirements and obligations.

        Exclusion Criteria:

          1. Ongoing, active pancreatitis at the time of the procedure.

          2. Known adverse reaction to secretin.

          3. Recent (within one month) use of medication that can potentially cause pancreatitis,
             such as metronidazole, tetracycline, sulfonamides.

          4. Use of anticholinergic medication within 7 days of study.

          5. Pregnant women, nursing mothers, or women of childbearing potential not employing
             appropriate contraception. Acceptable methods of birth control are: intrauterine
             device, implantable progesterone device, progesterone intramuscular injection, oral
             contraceptive (started at least one month prior to Visit 1 and continuing for the
             duration of the trial), contraceptive patch, condoms with spermicide or abstinence.

          6. Any medical condition which in the judgment of the Principal Investigator makes
             participation of the patient in the study medically unwarranted.

          7. Known complete obstruction of the pancreatic duct.

          8. Patients who have received an investigational product/drug or device within 30 days
             prior to Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Burton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2010</study_first_submitted>
  <study_first_submitted_qc>March 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2010</study_first_posted>
  <results_first_submitted>June 7, 2011</results_first_submitted>
  <results_first_submitted_qc>October 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2011</results_first_posted>
  <last_update_submitted>December 2, 2011</last_update_submitted>
  <last_update_submitted_qc>December 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genetic End Marker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Secretin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ChiRhoStim</title>
          <description>Human Secretin for Injection 0.1 mL/kg IV</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Saline for Injection 0.1 mL/kg IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ChiRhoStim</title>
          <description>Human Secretin for Injection 0.1 mL/kg IV</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Saline for Injection 0.1 mL/kg IV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The demographic data represents the intent to treat group when data was provided in cases where no demographic data was provided for a parameter, the number of observations was correspondenly reduced.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="15.5"/>
                    <measurement group_id="B2" value="47.2" spread="12.3"/>
                    <measurement group_id="B3" value="48.3" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endoscopic Sample</title>
        <description>Is Volume ≥ 3.5 mL Is HCO3 concentration ≥ 40 mEq/L Is DNA mutational analysis (K-ras-2 gene Fluorescence peak height ≥ 50 Relative Florescence Units panel assessable markers informative ≥ 8).
(Note- The outcome value is boolean (yes or no) as an answer).</description>
        <time_frame>First 5 minutes after treatment administration</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Fluid ≥ 3.5mL (Boolean Expression Evaluated as Yes or no).</title>
        <description>Volume of pancreatic fluid. The volume is the number of mL of pancreatic fluid.</description>
        <time_frame>First 5 minutes after treatment administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ChiRhoStim</title>
            <description>Human Secretin for Injection 0.1 mL/kg IV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline for Injection 0.1 mL/kg IV</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Fluid ≥ 3.5mL (Boolean Expression Evaluated as Yes or no).</title>
          <description>Volume of pancreatic fluid. The volume is the number of mL of pancreatic fluid.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ChiRhoStim</title>
          <description>Human Secretin for Injection 0.1 mL/kg IV</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Saline for Injection 0.1 mL/kg IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edward Purich, Ph.D.</name_or_title>
      <organization>ChiRhoClin, Inc.</organization>
      <phone>301-476-8388</phone>
      <email>mdoerr@chirhoclin.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

